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VCP/p97 is a multifunctional AAA+-ATPase involved in vesicle fusion, proteasomal degradation, and
autophagy. Reported dysfunctions of these processes in Alzheimer disease (AD), along with the link-
age of VCP/p97 to inclusion body myopathy with Paget’s disease and frontotemporal dementia
(IBMPFD) led us to examine the possible linkage of VCP to the AD-relevant protein, tau. VCP levels
were reduced in AD brains, but not in the cerebral cortex of an ADmouse model, suggesting that VCP
reduction occurs upstream of tau pathology. Genetic reduction of VCP in a primary neuronal model
led to increases in the levels of tau phosphorylated at Ser262/356, indicating that VCP may be involved
in regulating post-translational processing of tau in AD, demonstrating a possible functional linkage
between tau and VCP.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Valosin-containing protein (VCP) (also known as p97) is a mul-
tifunctional AAA+ (ATPase associated with various cellular activi-
ties) protein involved in a wide variety of cellular functions
including cytosolic proteasomal degradation [1] and autophagy
[2]. VCP has been shown to interact with various proteins impli-
cated in neurodegenerative diseases including ataxin-3 [3] and
huntingtin [4]. In 2004 it was discovered that the autosomal
-dominant degenerative disease Inclusion Body Myositis with Pa-
get’s disease of the bone and Frontotemporal Dementia (IBMPFD)
was linked to the VCP gene [5]. Affected tissue in this disorder con-
tains both cytoplasmic and nuclear insoluble protein aggregates
that are both ubiquitin- and VCP-positive [6].
Though the mechanistic role of VCP in endoplasmic reticulum
associated degradation (ERAD) is well described [7], a full under-
standing of its role in cytosolic protein degradation has been more
elusive. Genetic reduction of VCP results in large increases of ubiq-
uitylated proteins and ubiquitin-positive aggregates [8]. VCP has
been implicated in proteasomal degradation of ataxin-3 [3] and
huntingtin [4], as well as the formation of proteinaceous aggre-
gates [9]. In addition, it has been demonstrated that these aggre-chemical Societies. Published by E
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Francisco, CA, United States.gates contain the autophagosome markers LC3-II and p62 [2].
This dual role of VCP in both proteasomal degradation and autoph-
agy suggests a central role of VCP in determining the degradative
fate of aggregative proteins.
The main pathological hallmarks of Alzheimer disease (AD) are
beta-amyloid (Aß) plaques and neuroﬁbrillary tangles composed of
the microtubule-associated protein tau. Dysfunction in both the
ubiquitin-proteasome system [10] and autophagic clearance path-
ways [11] have been proposed as potential contributors to the
accumulation of both Aß and tau in AD. In particular, tau has been
described as a substrate of both the proteasome [12] and autoph-
agy pathway [13] and in a previous study our lab showed that a
C-terminal cleavage event was an important factor in directing
tau towards autophagic rather than proteasomal degradation
[14]. Because of VCP’s dualistic nature in modulating protein deg-
radation, as well as case studies indicating accumulations of
phospho-tau in IBMPFD cortex [15], we examined VCP protein
content in AD brain and the effect of VCP reduction on total and
phospho-tau levels in a neuronal model.
2. Materials and methods
2.1. Antibodies and plasmids
Tau antibodies usedwere: Tau5 (provided by Dr. L. Binder), PHF1
(provided by Dr. P Davies), and 12E8 (provided by Dr. P. Seubert).
Other antibodies used were anti-VCP (Afﬁnity Bioreagents), anti-lsevier B.V. All rights reserved.
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shuttle vectors were constructed by subcloning the cassette con-
taining the H1 promoter and shRNA sequence from pSU-
PER.retro.p97 and pSUPER.retro.ran1 [16] followed by ligation into
the vector FG12 (Addgene). The vectors pVSV-G (encoding the viral
envelope) and psPAX2 (encoding gag-pol) were from Addgene.org.
The identities of the constructs were conﬁrmed by DNA sequencing.
2.2. Tissue fractionation
Human brain samples were prepared as described previously
[17]. The protocol was designated as exempt by the Institutional
Review Boards of University of Alabama at Birmingham and the
University of Rochester. Information on the cases used in this study
is provided in Table 1. 3Tg-AD [18] and background-matched
non-transgenic (NTg) mice were housed in microisolators, and all
experiments were in compliance with University of Rochester
Committee on Animal Resources guidelines. Aged animals (NTg:
26 months, 3Tg-AD: 13–26 months) were anesthetized by intra-
peritoneal injection of nembutol (100 mg/kg), and transcardiac
perfusion was performed using PBS. Brains were removed, and cor-
tices dissected and immediately snap-frozen until use. Homogeni-
zation was performed exactly as for human brain tissue.
2.3. Lentiviral vector production
HEK 293TN cells were transfected with pLenti/psPAX2/pVSV-G
using Lipofectamine 2000 (Invitrogen). Twelve hours post
-transfection, media was replaced with DMEM supplemented with
1% Fetalclone II and 2 mM L-glutamine, and the cells were incu-
bated at 33 C. Forty-eight hours later the media was collected,
spun at 500g for 10 min at room temperature and the resulting
supernatant was then spun at 60,000g for 2 h at 4 C. The visible
pellet was resuspended in 500 ll sterile PBS containing 0.1% BSA
per 100 mm dish, and the lentiviral solution was either used
immediately or snap-frozen for later use.
2.4. Primary neuronal culture and transduction
Primary cortical neuronal cultures from rat embryonic forebrain
were prepared and maintained as described previously [19]. On
DIV 1, 25 ll of virus was added directly to the media on the neu-
rons, and medium replaced after 4 h. Experiments were performed
on DIV 7–8. For treatment with autophagy inhibitor, neurons were
treated with either vehicle or 10 mM 3-methyladenine (3-MA;
Sigma–Aldrich) for 12 h and collected on DIV 8. Neuronal viability
was determined using resazurin, as previously described [14].
2.5. Sarkosyl fractionation, immunoblotting, and qRT-PCR
Neurons were washed once with cold PBS and sarkosyl lysis
buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% sodium N-lauryl sar-Table 1
Patient information of cortical specimens examined in Fig. 1.
Specimen Age Sex PMI (h) Diagnosis
C1 83 M NA Hemorrhagic gastritis
C2 70 F NA Coronary artery disease
C3 65 M 6 Lymphoma
C4 79 F 22 Heart failure
C5 63 M 12 Hepatitis/cirrhosis
AD1 85 M 2.5 AD
AD2 74 M 11 AD
AD3 NA F NA AD
AD4 64 M 6 AD
AD5 78 F 4 AD
AD6 79 F 5 ADkosamine) was added directly to cells. Plates were incubated at
4 C for 30 min, and samples were brieﬂy sonicated and incubated
30 min at 25 C with occasional vortexing. Samples were centri-
fuged at 3000g for 20 min at 4 C, and supernatants were centri-
fuged further at 150,000g for 2 h at room temperature using a
benchtop airfuge (Beckman) to separate sarkosyl-soluble and -
insoluble fractions. Immunoblotting was carried out as previously
described [14]. Quantitative RT-PCR was carried out as described
previously [20].
2.6. Statistics
Analyses of differences in protein levels (Figs. 1, 2, and 4, 5)
were determined using Student’s t-test. Differences in cDNA levels
by qRT-PCR (Fig. 3) were analyzed using one-way ANOVA and post-
hoc t-tests. A threshold of p < 0.05 was used for determining signif-
icance. All data are expressed as means ± SEM.
3. Results
3.1. VCP protein levels are reduced in AD brain
Soluble protein lysates obtained from 5 control and 6 AD cortex
tissue samples (Table 1) were immunoblotted for VCP and actin
(Fig. 1A). Donors were similar in age (Control: 72 ± 3.9 y; AD:
76 ± 3.5 y). Band densitometry was performed and VCP levels were
normalized to actin. Despite some variance in VCP levels in AD
samples, the amount of VCP protein was signiﬁcantly reduced in
AD compared to the control samples (42.7 ± 19.1%) (Fig. 1B). In
contrast, this reduction in VCP levels was not observed in aged
3Tg-AD mice (Fig. 2).
3.2. Knockdown of VCP levels in rat primary cortical neurons
Primary rat cortical neurons transduced with shRNA targeted to
VCP were used to model the lowered levels of VCP found in AD0
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Fig. 1. VCP levels are lower in AD brain cortex than in age-matched controls. (A)
Frozen tissue from ﬁve control and six AD patients were homogenized and
fractionated, and equal amounts of homogenate were immunoblotted for VCP and
actin. (B) Quantiﬁcation of VCP immunoblotting described in (A). Protein levels
were quantiﬁed by scanning densitometry, normalized to actin, and expressed as
arbitrary units (A.U.). ⁄p < 0.05.
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Fig. 2. VCP levels in the cortex of 3Tg-AD and NTg mice are similar. (A) Cortical
tissue samples from 4 non-transgenic (NTg) (26 months) and 8 triple transgenic
(3Tg) (13–22 months) were processed identically to human tissue in Fig. 1.
Lysates were immunoblotted for VCP and actin. (B) Quantiﬁcation of immunoblot-
ting described in (A), protein levels were quantiﬁed by scanning densitometry,
normalized to actin, and expressed as arbitrary units (A.U.). There was no signiﬁcant
difference between the two groups.
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Fig. 3. VCP knockdown results in increased ubiqitylated proteins and decreased
viability. (A) Rat primary cortical neurons infected with shRNA-expressing lenti-
virus targeted to either VCP or a scrambled non-targeting sequence. Lysates were
immunoblotted for VCP, ubiquitylated conjugates (FK2), and actin. (B) Neurons
were infected as in (A), and subjected to a resazurin viability assay on DIV 8. (C)
Neurons were infected as in (A), and RNA was collected on DIV8 for qRT-PCR. Data
are normalized to the housekeeping gene actin and expressed as a ratio of cDNA
levels in VCP knockdown cultures compared to control cultures. ⁄p < 0.05.
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revealed a resulting accumulation of ubiquitylated conjugates, as
well as a decrease in cell viability [8]. Neurons were transducedon DIV 1, and lysates were collected on DIV 7–8. Using this para-
digm, VCP levels were consistently lowered 70–80% in comparison
to neurons equivalently transduced with control shRNA. In addi-
tion, ubiquitylated conjugates accumulated upon VCP knockdown,
in accordance with previous studies (Fig. 3A). The viability of neu-
rons transduced either with control or VCP shRNA was determined
using the resazurin metabolic assay, and the viability of VCP
shRNA-infected neurons was found to be signiﬁcantly reduced by
26.5 ± 3.5% (Fig. 3B). To ensure the speciﬁcity of shRNA targeting,
the message levels of four different proteins were examined: (1)
VCP, its functional homologue N-ethylmaleimide Sensitive Factor
(NSF), (3) the VCP-associated protein p47, and (4) tau. RNA was ex-
tracted from neurons transduced with control or VCP shRNA and
assayed using qRT-PCR. Transduction with VCP shRNA resulted in
the speciﬁc reduction of VCP message (38.1 ± 7.1%) compared to
control (Fig. 3C). NSF and p47 were both increased, but not signif-
icantly (126 ± 31% and 133 ± 29%, respectively). Tau cDNA levels
were lowered slightly but not signiﬁcantly (85 ± 16%).3.3. Soluble tau phosphorylated at Set262/356 phosphorylation
is increased as a result of VCP reduction
Because of the central role of VCP in both proteasomal and auto-
phagic degradation, we examined steady state tau levels in neurons
with reduced VCP expression. In addition, it has been demonstrated
that the sensitivity of tau to either the proteasome or autophagy
systems can be determined by post-translational processing, such
as phosphorylation [21]. Therefore we examined whether there
were changes in the levels of phosphorylated tau as a result of
VCP knockdown. Primary rat cortical neuronswere transducedwith
control and VCP shRNA lentivirus on DIV1, subjected to sarkosyl
fractionation on DIV 8, and immunoblotted (Fig. 4A). Reduction of
VCP levels resulted in a signiﬁcant reduction in the levels of soluble
total tau levels to 33.5 ± 6.8% of control levels (Fig. 4B). While the
phosphorylation of the PHF1 epitope (Ser396/404) remained un-
changed, 12E8 phosphorylation (Ser262/356) immunoreactivity was
signiﬁcantly increased to 561 ± 134% as a result of the reduction
of VCP levels. No changes in total or Ser262/356-phosphorylated tau
were observed in the sarkosyl-insoluble fractions (Fig. 4C).
3.4. Treatment with the macroautophagy inhibitor 3-methyladenine
results in increases in tau phosphorylated at Ser262/356
Because of its multivariate involvement in autophagy, proteaso-
mal degradation, and aggresome formation, VCP may play an
important modulatory role in determining the stability and degra-
dation of tau. The expression of dysfunctional mutants of VCP re-
lated to IBMPFD has been found to result in increased
accumulation of puncta containing processed LC3-II, a hallmark
of dysfunction in the autophagosome maturation pathway [2]. In
order to determine if autophagic inhibition resulted in similar in-
creases in the levels of soluble Ser262/356-phosphorylated tau that
we noted in neurons with reduced VCP levels, neurons were trea-
ted with either vehicle or 10 mM 3-MA for 16 h prior to collection
of lysates, and changes in 12E8, PHF1, and Tau5 immunoreactivity
were measured in the soluble fraction (Fig. 5A). There was a signif-
icant increase in the amount of 12E8 immunoreactivity upon treat-
ment with 3-MA (227 ± 65.9%) (Fig. 5B). This is in concordance
with previous ﬁndings in a different cell model which also reported
increases in 12E8 immunoreactivity upon 3-MA treatment [22].
4. Discussion
Tau is degraded through multiple clearance pathways, and it is
likely that a signiﬁcant factor dictating the pathway by which tau
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Fig. 4. Knockdown of VCP results in decreases in total soluble tau protein, but increases in soluble phosphorylated Ser262/356-tau protein. (A) Neurons were harvested on DIV 8
and fractionated using sarkosyl buffer. Equal amounts of soluble protein were immunoblotted for VCP, Tau5 (total tau) PHF1 (Ser396/404), 12E8 (Ser262/356) and actin. (B)
Quantiﬁcation of data described in (A). Tau5 immunoreactivity is normalized to actin, and PHF1 and 12E8 are both normalized to the Tau5/actin ratio. There was a signiﬁcant
difference in total tau and 12E8 levels (⁄p < 0.05) between control and VCP shRNA-infected groups (n = 9 from three different animals). Note that even though PHF1 levels are
lower for shRNA-VCP, there is no difference when this is normalized to Tau5/actin. (C) Sarkosyl-insoluble pellets were resolubilized, and equal volumes of resulting sample
were immunoblotted for Tau5, PHF1, and 12E8. (D) Quantiﬁcation of data described in (C). For sarkosyl-insoluble pellets, there was no signiﬁcant difference in any of the
epitopes as a result of shRNA-mediated knockdown of VCP.
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tant to examine the proteins that may be directing the processes
that regulate the degradation of tau by these different pathways,
as their study may provide insights into the mechanisms that reg-
ulate the fate of tau in different physiological and pathological
states. These mechanisms may occur either through direct binding
and tethering of tau to degradative processes, or through indirect
regulation of tau stability through an intermediary. It has already
been shown that tau interacts with p62 [23] and histone deacetyl-
ase 6 (HDAC6) [17], which both contain ubiquitin- and LC3-binding
capacities. Another such protein is VCP, which is involved in both
delivery of substrates to the proteasome [24] and autophagosome
formation [25]. In this study we show that total VCP levels are re-
duced in the cortex of sporadic AD cases. When VCP levels were re-
duced by shRNA in primary cortical neurons there was a signiﬁcant
increase in soluble tau phosphorylated at Ser262/356 as indicated by
an increase in 12E8 immunoreactivity. We also observed that total
soluble tau levels as measured by Tau5 immunoreactivity weredecreased when VCP levels were reduced. No changes in tau levels
were observed in the insoluble fraction upon VCP knockdown.
A recent study determined that in AD brain VCP is cleaved by
caspase 6 resulting into two N-terminal fragments of 28 and
20 kDa. These fragments inhibit the ubiquitin-proteasome system
by effectively acting as competitive inhibitors of both ubiquitylat-
ed substrates and N-terminal binding co-factors, and also act as
destabilizers of steady-state VCP levels [26]. In this present study
these 28 and 20 kDa VCP fragments were not observed in AD brain
samples, but it should be noted that the VCP antibody we used is
speciﬁc for the C-terminus of VCP. We did note lower levels of
VCP in AD brain, which could corroborate this ﬁnding of the N-ter-
minal cleavage of VCP. It is difﬁcult to positively determine a cor-
relation between these observations, as the previous study did not
examine total levels of VCP in human brain, but rather examined
the appearance of the N-terminal fragments using a speciﬁc anti-
body raised against the cleavage site. The lack of similar results
in 3Tg-AD mice indicates that VCP reduction occurs upstream
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Fig. 5. Inhibition of macroautophagy with 3-methyladenine results in increased
levels of 12E8 immunoreactivity. (A) Rat primary cortical neurons were infected on
DIV 1 with lentivirus expressing a scrambled non-targeting sequence, and treated
on DIV8 for 16 h with either vehicle or 10 mM 3-methyladenine (3-MA). Equal
amounts of lysate were blotted for Tau5, PHF1, 12E8, and actin. (B) Quantiﬁcation of
data described in (A). Normalization was performed as described in Fig. 4. ⁄p < 0.05.
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incurred by either of these proteins.
Knockdown of VCP resulted in a signiﬁcant increase in soluble
tau phosphorylated at the Ser262/356 sites as evidence by an almost
sixfold increase in 12E8 immunoreactivity. Tau’s Ser262/356 sites lie
within the microtubule binding domains, and are primary determi-
nants of tau afﬁnity for microtubules. The phosphorylation status
of tau may impact its particular degradative fate as it has been re-
ported that tau phosphorylated at Ser199/202 and Thr205 has an in-
creased propensity for ubiquitylation [12]. In contrast, tau
phosphorylated at the KXGS motifs is not degraded by the protea-
some [21], but rather by autophagy [22]. VCP is required for the
completion of macroautophagy, so one possible mechanism for
the increase of 12E8-tau when VCP levels are reduced is that
autophagy is inhibited, and this is very selective in preventing
the degradation of tau phosphorylated at Ser262/356, while other
forms of tau in the neuron are degraded. Indeed, inhibition of
autophagy with 3-MA resulted in a selective increase in tau phos-
phorylated at Ser262/356.
We also observed that knocking down VCP resulted in a de-
crease in soluble total tau levels as indicated by a decrease in
Tau5 immunoreactivity. This is in apparent conﬂict with the func-
tions of VCP that have been previously described – namely sub-
strate delivery to the proteasome and autophagic vacuole
maturation. A possible explanation for the reduction in tau levels
noted here is that VCP plays a role in maintaining the stability of
particular post-translationally modiﬁed forms of tau protein, while
leaving others unperturbed. A role for VCP in maintaining proper
folding and stability of substrate proteins is not unprecedented.
Rumpf and Jentsch [27] outline a model by which the ubiquityla-
tion and proteasome-targeting activity of VCP, when bound tothe E4 ligase Ufd2, can be counteracted by either simultaneous
binding of either the deubiquitylase Otul or the competing cofactor
Ufd3. This could result in the release of a substrate, possibly after
modiﬁcation of its ubiquitylation status to maintain proper folding
and stability. Alternatively, it is possible that VCP binds tau
through an alternate substrate binding region in the D2 loop of
VCP that has the capacity to bind hydrophobic patches of substrate
proteins [28]. One other distinct possibility that cannot be ruled
out is that changes in tau stability are an indirect result of the
reduction of VCP levels. VCP reduction results in the loss of cell via-
bility (Fig. 3; [8]), and the loss of neuronal integrity may be affect-
ing total and phosphorylated tau levels in the neuron. A recent
study [29] demonstrated that after antimycin A treatment, the
presence of Ser262/356-tau increases, while total tau and tau phos-
phorylated at Ser396/404 decreases. This was shown to be a result
of the speciﬁc recruitment of Ser262/356-tau to actin-coﬁlin rods.
While knockdown of VCP resulted in an increase in Ser262/356-tau,
a concomitant decrease in tau phosphorlyated at the Ser396/404 epi-
tope was not observed. Nevertheless, the similarities between the
twomodels are intriguing andmay underlie a commonmechanism
present during the early pathogenesis of AD. However it is clear
that further investigation is needed to determine the mechanisms
by which VCP regulates the stability/turnover of tau and how the
site speciﬁc phosphorylation state of tau determines its fate.
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